Biosimilars and Biologics in Medicare Part D: MedPAC briefing deck Via @medicarepayment #pharma #biotech goo.gl/awzqFL
Medicaid rebates on generic drugs and new inflatio…
posted on September 22, 2016 by
Medicaid rebates on generic drugs and new inflation adjustment. CMS issues clarification medicaid.gov/Medicaid-CHIP-… #pharma #Mylan #epipen
Drug Pricing Reform: Understanding Indication Spec…
posted on September 20, 2016 by
Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals #pharma #biotech #drugs… twitter.com/i/web/status/7…
Drug Pricing Reform: Understanding Indication Spec…
posted on September 19, 2016 by
Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals goo.gl/oM6V7w #pharma… twitter.com/i/web/status/7…
Biologics and Biosimilars: Backgrounder on FDA reg…
posted on September 15, 2016 by
Biologics and Biosimilars: Backgrounder on FDA regulatory issues, price comparisons, approvals goo.gl/qG2Twj #biotech #pharma
RT @sacjai: Drug pricing controversy focuses us on…
posted on August 30, 2016 by
RT @sacjai: Drug pricing controversy focuses us on enormous gap between public & #pharma industry self-perception mmm-online.com/features/pharm… #Mylan #EpiPen
RT @Behind_the_Pill: My latest post on #pharma #ge…
posted on August 14, 2016 by
RT @Behind_the_Pill: My latest post on #pharma #genetherapy #pricing is up! Check it out at behindthepill.com/whats-a-gene-t…
Drug companies offer money back guarantees for hig…
posted on August 14, 2016 by
Drug companies offer money back guarantees for high-cost, cutting-edge therapies #pharma #biotech flip.it/oLzNSO
FDA: Long list of guidance under development by Ce…
posted on August 12, 2016 by
FDA: Long list of guidance under development by Center for Drug Evaluation and Research (CDER). goo.gl/qhY8fc #pharma
NIH final rule expanding clinical trial reporting…
posted on August 2, 2016 by
NIH final rule expanding clinical trial reporting is at OMB. Reqs more info, adverse events sent to registry website #Pharma #FDA #Drugs
